Biotech News

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

Talphera Inc (TLPH)TalpheraEarnings

NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc.

Related news

Talphera Inc

Critical-Care Therapeutics Talphera develops hospital-based therapies intended to improve medication delivery in acute and critical-care settings. Its lead program addresses anticoagulation during continuous renal replacement therapy. Niyad Niyad is a regional citrate anticoagulant designed for use in the extracorporeal circuit during...

Recent company news

Stock data

Close
0.74 USD
Market cap
40.24M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States